These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34654610)

  • 1. Muscular dystrophy-dystroglycanopathy in a family of Labrador retrievers with a LARGE1 mutation.
    Shelton GD; Minor KM; Guo LT; Friedenberg SG; Cullen JN; Hord JM; Venzke D; Anderson ME; Devereaux M; Prouty SJ; Handelman C; Campbell KP; Mickelson JR
    Neuromuscul Disord; 2021 Nov; 31(11):1169-1178. PubMed ID: 34654610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LARGE expression in different types of muscular dystrophies other than dystroglycanopathy.
    Balci-Hayta B; Talim B; Kale G; Dincer P
    BMC Neurol; 2018 Dec; 18(1):207. PubMed ID: 30553274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Four-week rapamycin treatment improves muscular dystrophy in a fukutin-deficient mouse model of dystroglycanopathy.
    Foltz SJ; Luan J; Call JA; Patel A; Peissig KB; Fortunato MJ; Beedle AM
    Skelet Muscle; 2016; 6():20. PubMed ID: 27257474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exogenous expression of the glycosyltransferase LARGE1 restores α-dystroglycan matriglycan and laminin binding in rhabdomyosarcoma.
    Beltrán D; Anderson ME; Bharathy N; Settelmeyer TP; Svalina MN; Bajwa Z; Shern JF; Gultekin SH; Cuellar MA; Yonekawa T; Keller C; Campbell KP
    Skelet Muscle; 2019 May; 9(1):11. PubMed ID: 31054580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscular dystrophy in a family of Labrador Retrievers with no muscle dystrophin and a mild phenotype.
    Vieira NM; Guo LT; Estrela E; Kunkel LM; Zatz M; Shelton GD
    Neuromuscul Disord; 2015 May; 25(5):363-70. PubMed ID: 25813339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of a novel western blot assay to monitor patterns and levels of alpha dystroglycan in skeletal muscle of patients with limb girdle muscular dystrophies.
    Rajasingham T; Rodriguez HM; Betz A; Sproule DM; Sinha U
    J Muscle Res Cell Motil; 2024 Sep; 45(3):123-138. PubMed ID: 38635147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-terminal domain on dystroglycan enables LARGE1 to extend matriglycan on α-dystroglycan and prevents muscular dystrophy.
    Okuma H; Hord JM; Chandel I; Venzke D; Anderson ME; Walimbe AS; Joseph S; Gastel Z; Hara Y; Saito F; Matsumura K; Campbell KP
    Elife; 2023 Feb; 12():. PubMed ID: 36723429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muscular dystrophy associated with alpha-dystroglycan deficiency in Sphynx and Devon Rex cats.
    Martin PT; Shelton GD; Dickinson PJ; Sturges BK; Xu R; LeCouteur RA; Guo LT; Grahn RA; Lo HP; North KN; Malik R; Engvall E; Lyons LA
    Neuromuscul Disord; 2008 Dec; 18(12):942-52. PubMed ID: 18990577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRAPPC11 and GOSR2 mutations associate with hypoglycosylation of α-dystroglycan and muscular dystrophy.
    Larson AA; Baker PR; Milev MP; Press CA; Sokol RJ; Cox MO; Lekostaj JK; Stence AA; Bossler AD; Mueller JM; Prematilake K; Tadjo TF; Williams CA; Sacher M; Moore SA
    Skelet Muscle; 2018 May; 8(1):17. PubMed ID: 29855340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. POMK regulates dystroglycan function via LARGE1-mediated elongation of matriglycan.
    Walimbe AS; Okuma H; Joseph S; Yang T; Yonekawa T; Hord JM; Venzke D; Anderson ME; Torelli S; Manzur A; Devereaux M; Cuellar M; Prouty S; Ocampo Landa S; Yu L; Xiao J; Dixon JE; Muntoni F; Campbell KP
    Elife; 2020 Sep; 9():. PubMed ID: 32975514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal Skeletal Muscle Regeneration plus Mild Alterations in Mature Fiber Type Specification in Fktn-Deficient Dystroglycanopathy Muscular Dystrophy Mice.
    Foltz SJ; Modi JN; Melick GA; Abousaud MI; Luan J; Fortunato MJ; Beedle AM
    PLoS One; 2016; 11(1):e0147049. PubMed ID: 26751696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.
    Kanagawa M; Nishimoto A; Chiyonobu T; Takeda S; Miyagoe-Suzuki Y; Wang F; Fujikake N; Taniguchi M; Lu Z; Tachikawa M; Nagai Y; Tashiro F; Miyazaki J; Tajima Y; Takeda S; Endo T; Kobayashi K; Campbell KP; Toda T
    Hum Mol Genet; 2009 Feb; 18(4):621-31. PubMed ID: 19017726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ISPD gene mutations are a common cause of congenital and limb-girdle muscular dystrophies.
    Cirak S; Foley AR; Herrmann R; Willer T; Yau S; Stevens E; Torelli S; Brodd L; Kamynina A; Vondracek P; Roper H; Longman C; Korinthenberg R; Marrosu G; Nürnberg P; ; Michele DE; Plagnol V; Hurles M; Moore SA; Sewry CA; Campbell KP; Voit T; Muntoni F
    Brain; 2013 Jan; 136(Pt 1):269-81. PubMed ID: 23288328
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Christen M; Indzhova V; Guo LT; Jagannathan V; Leeb T; Shelton GD; Brocal J
    Genes (Basel); 2021 Nov; 12(11):. PubMed ID: 34828429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucocorticoid Steroid and Alendronate Treatment Alleviates Dystrophic Phenotype with Enhanced Functional Glycosylation of α-Dystroglycan in Mouse Model of Limb-Girdle Muscular Dystrophy with FKRPP448L Mutation.
    Wu B; Shah SN; Lu P; Richardson SM; Bollinger LE; Blaeser A; Madden KL; Sun Y; Luckie TM; Cox MD; Sparks S; Harper AD; Lu QL
    Am J Pathol; 2016 Jun; 186(6):1635-48. PubMed ID: 27109613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression.
    Kanagawa M; Yu CC; Ito C; Fukada S; Hozoji-Inada M; Chiyo T; Kuga A; Matsuo M; Sato K; Yamaguchi M; Ito T; Ohtsuka Y; Katanosaka Y; Miyagoe-Suzuki Y; Naruse K; Kobayashi K; Okada T; Takeda S; Toda T
    Hum Mol Genet; 2013 Aug; 22(15):3003-15. PubMed ID: 23562821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mouse fukutin deletion impairs dystroglycan processing and recapitulates muscular dystrophy.
    Beedle AM; Turner AJ; Saito Y; Lueck JD; Foltz SJ; Fortunato MJ; Nienaber PM; Campbell KP
    J Clin Invest; 2012 Sep; 122(9):3330-42. PubMed ID: 22922256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole exome sequencing identified a novel DAG1 mutation in a patient with rare, mild and late age of onset muscular dystrophy-dystroglycanopathy.
    Dai Y; Liang S; Dong X; Zhao Y; Ren H; Guan Y; Yin H; Li C; Chen L; Cui L; Banerjee S
    J Cell Mol Med; 2019 Feb; 23(2):811-818. PubMed ID: 30450679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HNK-1 sulfotransferase modulates α-dystroglycan glycosylation by 3-O-sulfation of glucuronic acid on matriglycan.
    Sheikh MO; Venzke D; Anderson ME; Yoshida-Moriguchi T; Glushka JN; Nairn AV; Galizzi M; Moremen KW; Campbell KP; Wells L
    Glycobiology; 2020 Sep; 30(10):817-829. PubMed ID: 32149355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new patient-derived iPSC model for dystroglycanopathies validates a compound that increases glycosylation of α-dystroglycan.
    Kim J; Lana B; Torelli S; Ryan D; Catapano F; Ala P; Luft C; Stevens E; Konstantinidis E; Louzada S; Fu B; Paredes-Redondo A; Chan AE; Yang F; Stemple DL; Liu P; Ketteler R; Selwood DL; Muntoni F; Lin YY
    EMBO Rep; 2019 Nov; 20(11):e47967. PubMed ID: 31566294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.